ArticleCancers2020
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Genetic Profiling of Primary Versus Metastatic Ewing Sarcoma for Therapeutic Target Identification.Life (Basel, Switzerland) · 2026Article
- Systemic Therapy for Solitary Fibrous Tumor.Current treatment options in oncology · 2026Review
- Beyond the membrane: Internalization and compartmentalization of insulin‑like growth factor 1 receptor signaling in cancer pathogenesis and treatment (Review).International journal of oncology · 2026Review
- IGF-1R inhibitors in cancer: A review of available evidence and future outlook.Critical reviews in oncology/hematology · 2025Review
- New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee.Pediatric blood & cancer · 2025Review
- Targeting developmental vulnerabilities in childhood sarcomas.Cancer metastasis reviews · 2025Review
- Systemic strategies for osteosarcoma: advances and future directions.Discover oncology · 2025Review
- Microenvironment matters: insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy.Cancer metastasis reviews · 2025Review
- YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1-mediated reprogramming of bone mesenchymal stem cells.Cell reports · 2025Article
- Case Report: Should IGF-1R targeted therapy be revisited in Ewing sarcoma? a report of long-term complete response and review of the literature.Frontiers in oncology · 2025Article
- Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma.Nature communications · 2024Article
- Targeted treatment of solid tumors in pediatric precision oncology.Frontiers in oncology · 2023Review
- Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma.Cancers · 2022Review
- Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer.Journal of bone oncology · 2022Article
- A Proposed Trial Design for the Treatment of Widely Metastatic Ewing Sarcoma Inspired by Evolutionary Dynamics.Cancers · 2022Article
- One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.Journal of bone oncology · 2021Article
- Complete Purging of Ewing Sarcoma Metastases from Human Ovarian Cortex Tissue Fragments by Inhibiting the mTORC1 Signaling Pathway.Journal of clinical medicine · 2021Article
- Review
- Mediastinal lymph node metastasis as a single expression of disease relapse in Ewing's sarcoma: multidisciplinary approach of two consecutive cases.Intractable & rare diseases research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 1 country.
Hesham M AminDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ajaykumar C MoraniDepartment of Nuclear Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Najat C DawDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6941-8005
Salah-Eddine Lamhamedi-CherradiDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8324-4769
Vivek SubbiahDepartment of Investigational Cancer Therapeutics, 7Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6064-6837
Brian A MenegazBaylor College of Medicine, Department of Surgery, Breast Surgical Oncology, Houston, TX 77030, USA.
Deeksha VishwamitraDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ghazaleh EskandariDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bhawana GeorgeDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Robert S BenjaminDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shreyaskumar PatelDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Juhee SongDepartment of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Alexander J LazarDepartment of Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wei-Lien WangDepartment of Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Razelle KurzrockCenter for Personalized Cancer Therapy, University of California San Diego (UCSD) Moores Cancer Center, San Diego, CA 92037, USA.ORCID 0000-0003-4110-1214
Alberto PappoDepartment of Pathology, St. Jude's Cancer Research Hospital, Memphis, TN 38105, USA.
Peter M AndersonDepartment of Pediatric Oncology, Cleveland Clinic, OH 44195, USA.ORCID 0000-0002-0011-0969
Gary K SchwartzDivision of Hematology & Oncology, Columbia University Medical Center, New York, NY 10032, USA.
Dejka AraujoDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Branko CuglievanDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ravin RatanDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
David McCallDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-2297-9670
Sana MohiuddinDepartment of Pediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
John A LivingstonDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1337-3282
Eric R MolinaBaylor College of Medicine, Department of Surgery, Breast Surgical Oncology, Houston, TX 77030, USA.ORCID 0000-0003-2662-3524
Aung NaingDepartment of Investigational Cancer Therapeutics, 7Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joseph A LudwigDepartment of Sarcoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USCleveland Clinic · USColumbia University Irving Medical Center · USSt. Jude Children's Research Hospital · USUniversity of California San Diego · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MThree-dimensional Model of Human Ewing SarcomaR01CA180279 · NCI · RICE UNIVERSITY · PI KASPER, FRED KURTIS, LUDWIG, JOSEPH A · 2014 to 2018
$1.8MRole of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphomaR01CA151533 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M · 2011 to 2015
$1.6MFaris Virani Foundation N/AGaylord Foundation N/ANCI NIH HHS CA151533NCI NIH HHS CA16672NCI NIH HHS CA180279-01NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA151533NCI NIH HHS R01 CA180279Wells Alliance N/A
Abstract
PubMed holds no abstract for this paper.
Indexed as
biological therapiesbiomarkerdrug responseEwing sarcomaPET/CTpIGF-1R
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.